Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Handa Pharmaceuticals, Inc. (6620.TWO)
Tainan City, TW
Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -4.26% | -4.13% | -8.51% | -40.00% | -16.28% | -11.66% | -56.21% | +164.32% | -21.04% | -21.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+108.2% ★ Q1'26: -55.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+44.8% ★ Q1'26: -62.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.5% Q1'26: +98.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+54.0% ★ Q1'26: +27.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+37.3% ★ Q1'26: +11.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+9.6% Q1'26: +9.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.05× ★ Q1'26: 0.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
830.67M
est: 2.55B (-67.4%)
|
1.73B
est: 1.73B (+0.0%)
|
2.92B
2.92B – 2.92B
+68.8% YoY
|
4.93B
4.93B – 4.93B
+68.8% YoY
|
| EBITDA |
490.09M
est: 365.05M (+34.3%)
|
934.18M
est: 247.55M (+277.4%)
|
417.80M
417.80M – 417.80M
+68.8% YoY
|
705.13M
705.13M – 705.13M
+68.8% YoY
|
| EBIT |
479.66M
est: 313.74M (+52.9%)
|
934.18M
est: 212.76M (+339.1%)
|
359.08M
359.08M – 359.08M
+68.8% YoY
|
606.02M
606.02M – 606.02M
+68.8% YoY
|
| Net Income |
472.74M
est: 2.47B (-80.9%)
|
749.77M
est: 592.09M (+26.6%)
|
670.93M
670.93M – 670.93M
+13.3% YoY
|
862.63M
862.63M – 862.63M
+28.6% YoY
|
| SGA |
119.54M
est: 1.61B (-92.6%)
|
—
est: 1.09B (-100.0%)
|
1.85B
1.85B – 1.85B
+68.8% YoY
|
3.12B
3.12B – 3.12B
+68.8% YoY
|
| EPS |
3.37
est: 15.98 (-78.9%)
|
4.85
est: 3.83 (+26.6%)
|
4.34
4.34 – 4.34
+13.3% YoY
|
5.58
5.58 – 5.58
+28.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chi-Yu Yang | Vice President of Finance & Accounting Officer | — | female |
| Fang-Yu Liu | Founder & Chairman | — | male |
| Guo-Chun Song | Chief Technology Officer | — | — |
| Mei-Fang Chang | Senior Vice President of Quality Affairs & Director | — | female |
| Toshiyo Chen | GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6620.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
